Broken String Biosciences
Biotechnology company developing DNA break mapping technology (BREAK-seq) to enable safer cell and gene therapies by detecting off-target effects of gene editing tools.
Notes
Broken String Biosciences is a biotechnology company headquartered in Cambridge, UK, focused on developing advanced DNA break detection technology for safer cell and gene therapies. Their proprietary BREAK-seq platform enables precise mapping of DNA double-strand breaks, helping researchers and pharmaceutical companies identify off-target effects of gene editing tools like CRISPR-Cas9.
The company spun out of the Wellcome Sanger Institute and Cambridge University, leveraging foundational research in DNA damage detection. Their technology is used by gene therapy developers to improve the safety profile of gene editing-based treatments.
Team
- Felix Dobbs - Co-founder & Chief Executive Officer
- LinkedIn: linkedin.com/in/felixdobbs
- Simon Reed, Ph.D. - Co-founder & Chief Scientific Officer
- LinkedIn: linkedin.com/in/simonreed
Additional Research Findings
- Spun out from the Wellcome Sanger Institute and Cambridge University
- BREAK-seq technology for DNA break mapping and gene editing safety
- Focus on detecting off-target effects of CRISPR and other gene editing tools
- Serves pharmaceutical and biotech companies developing gene therapies
- Based in Cambridge, UK biotech cluster
- Supports safer development of cell and gene therapies
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Illumina Ventures | San Francisco, California, USA | biotech-focused | seedseries-a+1 | 32 |